MX2021000456A - Compuesto triciclico fusionado como inhibidor dual pde3/pde4. - Google Patents

Compuesto triciclico fusionado como inhibidor dual pde3/pde4.

Info

Publication number
MX2021000456A
MX2021000456A MX2021000456A MX2021000456A MX2021000456A MX 2021000456 A MX2021000456 A MX 2021000456A MX 2021000456 A MX2021000456 A MX 2021000456A MX 2021000456 A MX2021000456 A MX 2021000456A MX 2021000456 A MX2021000456 A MX 2021000456A
Authority
MX
Mexico
Prior art keywords
pde3
cyclic compound
pde4
dual inhibitor
fused tri
Prior art date
Application number
MX2021000456A
Other languages
English (en)
Inventor
Jianfeng Pan
Yunfu Luo
Guoli Zhang
Sheng Su
Yong Wang
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2021000456A publication Critical patent/MX2021000456A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona un compuesto tricíclico fusionado como inhibidor dual de PDE3/PDE4, y un uso del mismo en la preparación de fármacos para enfermedades asociadas a PDE3/PDE4, particularmente en funciones medicinales tales como enfermedad pulmonar obstructiva crónica (EPOC). Se proporcionan específicamente un compuesto de fórmula (|) y una sal farmacéuticamente aceptable del mismo. (Ver formula).
MX2021000456A 2018-07-13 2019-07-12 Compuesto triciclico fusionado como inhibidor dual pde3/pde4. MX2021000456A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810772374 2018-07-13
PCT/CN2019/095826 WO2020011254A1 (zh) 2018-07-13 2019-07-12 作为pde3/pde4双重抑制剂的三并环类化合物

Publications (1)

Publication Number Publication Date
MX2021000456A true MX2021000456A (es) 2021-07-21

Family

ID=69143182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000456A MX2021000456A (es) 2018-07-13 2019-07-12 Compuesto triciclico fusionado como inhibidor dual pde3/pde4.

Country Status (10)

Country Link
US (1) US11993596B2 (es)
EP (1) EP3822272A4 (es)
JP (1) JP7491896B2 (es)
KR (1) KR20210031727A (es)
CN (2) CN112368281B (es)
AU (2) AU2019302610B2 (es)
CA (1) CA3106052A1 (es)
IL (1) IL280075B1 (es)
MX (1) MX2021000456A (es)
WO (1) WO2020011254A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230060174A1 (en) * 2020-01-15 2023-03-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of tricyclic pde3/pde4 dual inhibitor compound
JP2023512471A (ja) * 2020-01-15 2023-03-27 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｐｄｅ３／ｐｄｅ４二重阻害剤の結晶及びその使用
CA3211820A1 (en) 2021-04-29 2022-11-03 Zhiya LI Isoquinolone compound and use thereof
WO2023109802A1 (zh) * 2021-12-14 2023-06-22 海思科医药集团股份有限公司 三环稠杂环类pde3/4双重抑制及其用途
WO2023138676A1 (zh) * 2022-01-21 2023-07-27 四川海思科制药有限公司 三环稠杂环类pde3/4双重抑制及其用途
WO2024088402A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种异喹啉酮类化合物的晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ185900A (en) 1976-12-10 1981-04-24 Hoechst Ag Pyrimido (6,1-a) isoquinolin-4-ones medicaments intermediate isoquinolines
FI64370C (fi) * 1977-05-05 1983-11-10 Hoechst Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara pyimido-(6,1-a)isokinolin-2-imino-4-onderivat
ZW6284A1 (en) * 1983-05-05 1985-10-30 Hoffmann La Roche Novel pyrimidone derivatives
EP1022868B1 (en) 1998-07-22 2004-11-24 Mitsubishi Denki Kabushiki Kaisha Mobile communication system and mobile communication method
DE60005493T2 (de) * 1999-03-31 2004-07-01 Vernalis Ltd., Wokingham Pyrimido[6,1-a]isochinolinonderivate
PL2603509T3 (pl) 2010-08-09 2014-11-28 Verona Pharma Plc Krystaliczna postać związku pirymidio[6,1-a]izochinolin-4-onowego

Also Published As

Publication number Publication date
JP7491896B2 (ja) 2024-05-28
CN112368281B (zh) 2022-02-18
WO2020011254A1 (zh) 2020-01-16
AU2024201135A1 (en) 2024-03-14
EP3822272A4 (en) 2022-04-06
CA3106052A1 (en) 2020-01-16
IL280075B1 (en) 2024-02-01
US11993596B2 (en) 2024-05-28
CN114644630A (zh) 2022-06-21
KR20210031727A (ko) 2021-03-22
AU2019302610B2 (en) 2023-11-23
JP2021532088A (ja) 2021-11-25
IL280075A (en) 2021-03-01
US20210323960A1 (en) 2021-10-21
EP3822272A1 (en) 2021-05-19
AU2019302610A1 (en) 2021-03-04
CN112368281A (zh) 2021-02-12

Similar Documents

Publication Publication Date Title
MX2021000456A (es) Compuesto triciclico fusionado como inhibidor dual pde3/pde4.
PH12020551305A1 (en) Pharmaceutical Compounds
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
BR112015012693A2 (pt) derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral
JO3805B1 (ar) مثبطات كراس جي12سي
AU2016354007A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2018004364A (es) Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
MX2020012180A (es) Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina.
JP2017504611A5 (es)
MX2019002541A (es) Derivados de pirimidina contra virus de la influenza.
PH12015500313A1 (en) Orally administered medical composition
WO2011106729A3 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
CR20210213A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA201792591A1 (ru) Фармацевтические препараты
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
HUP0400222A2 (hu) PDE-4 inhibitort és H1 receptor antagonistát tartalmazó kombináció és ennek alkalmazása tüdőbetegségek kezelésére alkalmas gyógyszerkészítmény előállítására
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor